SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Slattery, J.T. Articles by Appelbaum, F.R. Search for Related Content PubMed PubMed Citation Articles by Slattery, J.T. Articles by Appelbaum, F.R. Related Collections Transplantation Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 89 No. 8 (April 15), 1997: pp. 3055-3060 Marrow Transplantation for Chronic Myeloid Leukemia: The Influence of Plasma Busulfan Levels on the Outcome of Transplantation By J.T. Slattery, R.A. Clift, C.D. Buckner, J. Radich, B. Storer, W.I. Bensinger, E. Soll, C. Anasetti, R. Bowden, E. Bryant, T. Chauncey, H.J. Deeg, K.C. Doney, M. Flowers, T. Gooley, J.A. Hansen, P.J. Martin, G.B. McDonald, R. Nash, E.W. Petersdorf, J.E. Sanders, G. Schoch, P. Stewart, R. Storb, K.M. Sullivan, E.D. Thomas, R.P. Witherspoon, and F.R. Appelbaum From the Fred Hutchinson Cancer Research Center, Seattle; and the Veterans Administration Medical Center, Seattle, WA.     ABSTRACT Abstract Introduction Methods Results Discussion References The influence of busulfan (BU) plasma concentration on outcome of transplantation from HLA identical family members for the treatment of chronic myelogenous leukemia (CML) was examined in 45 patients transplanted in chronic phase (CP) (n = 39) or accelerated phase (AP) (n = 6). All patients received the same regimen of BU, 16 mg/kg orally and cyclophosphamide (CY), 120 mg/kg intravenously. Plasma concentrations of BU at steady state (CSSBU) during the dosing interval were measured for each patient. The mean CSSBU was 917 ng/mL (range, 642 to 1,749; median, 917; standard deviation, 213). Of patients with CSSBU below the median, seven (five of 18 in CP and two of four in AP) developed persistent cytogenetic relapse and three of these patients died. There were no relapses in patients with CSSBU above the median. The difference in the cumulative incidence of relapse between the two groups was statistically significant (P = .0003). CSSBU was the only statistically significant determinant of relapse in univariable or multivariable analysis. The 3-year survival estimates were 0.82 and 0.64 for patients with CSSBU above and below the median (P = .33). There was no statistically significant association of CSSBU with survival or nonrelapse mortality, although the power to detect a difference in survival between 0.82 and 0.64 was only 0.24, similarly CSSBU above the median was not associated with an increased risk of severe regimen-related toxicity. We conclude that low BU plasma levels are associated with an increased risk of relapse.     INTRODUCTION Abstract Introduction Methods Results Discussion References ALLOGENEIC MARROW transplantation from HLA identical siblings is the most effective treatment for chronic myelogenous leukemia (CML).1-4 The results of transplantation have improved over the past 10 years,4-7 and the best results are obtained when patients are transplanted early during chronic phase (CP). In a recent Seattle study,8 the 4-year probability of survival for 128 patients transplanted within 1 year of diagnosis after conditioning with either busulfan and cyclophosphamide (BU + CY) or cyclophosphamide and total body irradiation (CY + TBI) was 0.86. In a prospective randomized study9 of marrow transplantation for patients with CML in CP, we demonstrated that the BU + CY regimen was better tolerated than and associated with survival and relapse probabilities, which compared favorably to the CY + TBI regimen. All patients received methotrexate (MTX) and cyclosporine (CSP) as prophylactic immunosuppression against acute graft-versus-host disease (GVHD). Since November 1992, all patients older than 14 years with CML in CP or accelerated phase (AP) receiving transplants from HLA-identical related donors have been conditioned with the BU + CY + MTX + CSP regimen and through 1995, we have transplanted 168 patients in CP using this regimen. It has been demonstrated that patients receiving oral BU achieve widely varying plasma concentrations and that low concentrations predispose to graft rejection,10 while high levels increase the risk of toxicity.10,11 The antileukemic effect of the BU + CY regimen putatively resides largely in BU, and it is possible that higher levels will protect against relapse of CML. It is important to evaluate this possibility because variations in BU plasma concentration can be overcome with a high degree of accuracy by individually adjusting the oral dose to achieve a desired target concentration.12 In the present report, we evaluate the influence of plasma BU levels on relapse and survival in patients transplanted for the treatment of CML at the Fred Hutchinson Cancer Research Center (Seattle, WA) using a BU + CY regimen.     MATERIALS AND METHODS Abstract Introduction Methods Results Discussion References Patient Eligibility and Accrual Between 1991 and 1995, BU pharmacokinetics were studied in 45 patients with CML in CP (n = 39) or AP (n = 6) undergoing marrow transplantation from HLA-identical family member donors. Patients were selected on the basis of the availability of laboratory resources and all patients selected are included in this report. The diagnosis of CML was established by standard criteria: all patients were Ph chromosome positive and were categorized as being in CP or AP on the basis of previously defined characteristics.4 Disease and phase status were confirmed immediately before transplantation. Informed Consent Risks of the treatment protocols were fully explained to the patients, donors, and relatives. Informed consent was obtained using forms approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. Treatment Regimen All patients in this study were conditioned for marrow transplantation with a regimen consisting of BU 1.0 mg/kg administered orally four times daily on each of 4 successive days (total dose, 16 mg/kg) followed by 60 mg/kg of CY administered intravenously on each of 2 successive days (total dose, 120 mg/kg). BU was administered as 2-mg tablets in gelatin capsules. Antiemetics were given in accordance with our standard practice, which includes ondansetron 8 mg orally before each BU dose, diphenhydramine 25 to 50 mg every 4 to 6 hours as needed, and lorazepam 0.5 to 2.0 mg every 4 to 6 hours as needed. Phenytoin was administered to all patients in accordance with our standard protocol, which includes a loading dose of 15 mg/kg divided among three doses before BU administration and maintenance dosing of 300 mg orally daily continued until 24 hours after the last dose of BU. Prophylaxis against acute GVHD consisted of MTX and CSP.13,14 All patients were scheduled to receive intravenous MTX 15 mg/m2 on day 1 and 10 mg/m2 on days 3, 6, and 11. CSP was administered intravenously at a dose of 3 mg/kg per day in two divided doses starting on the day before marrow infusion (day -1). Oral CSP, 12.5 mg/kg per day was substituted for intravenous administration when tolerated. Starting on day 50, oral CSP administration was tapered by 5% weekly and discontinued on day 180. Doses of CSP were adjusted if necessary (usually because of renal or hepatic dysfunction), and MTX administration was adjusted for severe mucositis, extravascular fluid accumulation, or impairment of renal function. Acute and chronic GVHD were diagnosed and graded using established criteria.15 Acute GVHD was treated with prednisone, antithymocyte globulin, or monoclonal antibodies.16,17 Chronic GVHD was treated with prednisone alone or with CSP.18,19 Tissue Typing Studies Forty-three donors were HLA genotypically identical siblings, one was a phenotypically identical father, and one was a phenotypically identical son, of the recipients as shown by serologic typing for HLA-A, B, DR, and DQ testing in mixed lymphocyte culture assays (recently replaced by typing for DRB and DQB alleles by hybridization of sequence specific oligonucleotide probes to PCR amplified DNA).20-22 Pharmacokinetic Studies Details of the chemical (gas chromatography/mass spectrometry) and pharmacokinetic analyses have been described.10 To provide accurate assessments of BU exposure during conditioning, blood samples were collected at 0, 1, 2, 4, and 6 hours after any two of the morning doses on days 2, 3, or 4 of BU administration (ie, the fifth, ninth, and 13th doses). CSSBU is the ratio of BU area under the curve (AUC) over the dosing interval to the time between doses (6 hours). The CSSBU evaluated as a determinant of outcome was the mean of the values observed in each patient. Regimen-Related Toxicity Regimen-related toxicity was scored using the criteria described by Bearman et al.23 The overall grade assigned was the maximum grade for the bladder, renal, pulmonary, hepatic, central nervous system (CNS), mucosal, and gastrointestinal organ systems during the first 28 days posttransplant. Engraftment and Rejection Evidence of graft rejection was sought in patients who relapsed. When a gender difference existed between donor and patient, in situ Y chromosome hybridization24 was performed on bone marrow and peripheral blood mononuclear cells stimulated with phytohemagglutinin. When patient and donor were of the same gender, DNA from bone marrow and peripheral blood mononuclear cells was amplified for several variable number tandem repeat (VNTR) loci. The amplified fragments were examined to identify informative host or donor markers.25 Relapse All patients were scheduled to have marrow samples examined by cytogenetic analysis on days 28, 56, 84, at 6-month intervals for 2 years, and then annually. One patient, who died with venoocclusive disease of the liver on day 34, did not have any posttransplant cytogenetic evaluations and could not be evaluated for relapse. Relapse was defined as the detection of Ph positive metaphases in the marrow after day 50 posttransplant. Relapse was further categorized as transient when Ph positive metaphases cleared from the marrow and subsequently remained undetectable without definitive therapeutic intervention. Otherwise, relapses were defined as persistent. Infection Blood samples were cultured weekly for the presence of cytomegalovirus (CMV). Interstitial pneumonia (IP) was diagnosed by culture, histology or histochemistry of bronchoalveolar lavage, open lung biopsy, or autopsy. Various infectious disease prophylaxis strategies were employed during this study including isolation in laminar air flow rooms, the prophylactic use of systemic antibiotics, fluconazole, acyclovir, ganciclovir, and the use of screened or filtered blood products.26 All CMV seronegative patients received either screened or filtered blood products. Acyclovir was given for prophylaxis to all herpes simplex virus seropositive patients throughout the study period. Ganciclovir was given to all CMV seropositive recipients at engraftment or at the first development of antigenemia.27-29 All patients received fluconazole.30 Causes of Death Deaths after persistent posttransplant relapse were categorized as due to leukemia irrespective of the proximate cause. Deaths in the absence of persistent relapse were categorized as nonrelapse mortality. Infection was listed as the cause of death when a bacterial, viral, or fungal infection other than IP was the proximate cause of death in patients who had not relapsed. Infections were further categorized according to their association with or without GVHD. Deaths due to IP formed a separate category. Statistical Analysis The endpoints examined included survival, relapse, mortality from causes other than relapse (nonrelapse mortality), and acute GVHD. Acute GVHD was measured as grade 2 or greater during the first 100 days posttransplant or as grade 3 or 4 during the first 100 days posttransplant. Estimates of survival were obtained by the method of Kaplan and Meier31,32 where patients were censored at last follow-up if still alive. Estimates of the incidence of persistent relapse and acute GVHD were obtained using cumulative incidence estimates,33 where death without persistent relapse was regarded as a competing risk for the endpoint of persistent relapse and death without acute GVHD was regarded as a competing risk for the endpoint of acute GVHD. Patients who did not reach the appropriate endpoint or fail from the appropriate competing risk were censored on the date of latest cytogenetic evaluation for evaluating relapse and on day 100 for evaluating acute GVHD in the cumulative incidence estimates. Proportional hazards regression analysis was performed on the endpoints survival, persistent cytogenetic relapse, and acute GVHD. Variables tested for association with outcome were CSSBU categorized as less than or greater than the median, age (categorized as less than or greater than 40 years), the interval from diagnosis to transplant (categorized as less than or greater than 1 year), donor gender, and the permutations of CMV seropositivity of patient and donor. The association of these variables with the hazard appropriate for each endpoint was examined in univariable analysis, and variables that showed statistically significant or suggestive associations were examined as covariables in multivariable analysis. All P values from these models were derived from the Wald test or from likelihood ratio tests where the Wald test could not be computed, and are two-sided. No adjustments were made for multiple comparisons. The data set was locked for recording events on November 1, 1996.     RESULTS Abstract Introduction Methods Results Discussion References Busulfan Levels Table 1 presents the distribution of CSSBU for the patients in this study. The mean of these levels was 917 ng/mL (range, 642 to 1,749) and the median level was 917 ng/mL. The median clearance was 3.03 mL/min/kg, comparable to previous observations in adults.10,11   View this table: [in this window] [in a new window]   Table 1. Distribution of CssBU in Study Patients (n = 45) Table 2 shows the patient characteristics at the time of transplant for the groups categorized as having CSSBU below or above the median. As shown, the two groups were generally similar except for a trend towards more younger patients in the group with higher CSSBU levels.   View this table: [in this window] [in a new window]   Table 2. Patient Characteristics Regimen-Related Toxicity (RRT) The median RRT score for patients above and below the median CSSBU was 1 and there was no statistically significant difference in the distribution of RRT scores between the two groups (Mann-Whitney test, P = .477). The most common RRT was mucositis (95% of patients) followed by veno-occlusive disease of the liver (VOD) (34%). Only one patient (CSSBU 833 ng/mL) developed severe RRT (grade 3 or 4), and that patient died on day 34 of VOD. Relapse Seven patients (five of 39 patients transplanted in CP and two of six transplanted in AP) had reappearance and persistence of Ph chromosomes in marrow cell metaphases after the transplant on days 57, 79, 183, 211, 227, 423, and 749. All relapses occurred in patients with CSSBU below the median value. In the group of 21 patients with CSSBU below the median who were evaluated for relapse, the median number of cytogenetic examinations before relapse was detected was four (range, three to seven), and the median number of metaphases examined in each test was 20 (range, one to 30). In the group of 23 patients with CSSBU at or above the median, the median number of cytogenetic examinations was four (range, three to nine), and the median number of metaphases examined was 20 (range, two to 30). Figure 1 shows the cumulative incidence estimates of persistent relapse for patients categorized as having CSSBU below (cumulative incidence, 0.384) or above (cumulative incidence, 0.000) the median. The difference between the groups was statistically significant (P = .0009 univariate). In univariable Cox analysis, no other variable was significantly associated with relapse. However, because previous experience in larger series had demonstrated an association of relapse with donor gender and with age, the association of CSSBU with relapse was examined in multivariable analysis, and the P value was .0003 after adjustment for male donor and age greater than 40 years. View larger version (13K): [in this window] [in a new window]   Fig 1. The cumulative incidence of relapse for patients transplanted for CML in CP or AP categorized on the basis of BU steady state concentrations (CSSBU) greater than or less than the median (917 ng/mL) during conditioning. Patients were censored on the date of last cytogenetic examination. One patient who died on day 34 did not have any posttransplant cytogenetic examinations and was not evaluated for relapse. Tic marks denote patients at risk of relapse. The difference between the groups is statistically significant (P = .0009). Graft Rejection All patients achieved functional marrow engraftment and there were no significant differences between the groups of patients with CSSBU above or below the median for speed of engraftment as measured by the days on which granulocytes reached 100/µL (medians, 14 and 15, respectively, P = .54) or 500/µL (medians, 20 and 24, respectively, P = .52) or the days after which platelets were maintained without transfusion at 20,000/µL for 7 days (medians, 20 and 21 days, respectively, P = .26). Tests for chimerism demonstrated persistent donor hematopoiesis in all of the patients who relapsed. Survival Eleven patients (nine of 39 patients transplanted during CP and two of six patients transplanted during AP) have died. Four of the deaths occurred in patients who had CSSBU above the median, and seven deaths were in patients with CSSBU below the median. Three of the CP patients died of disseminated aspergillosis on days 114, 211, and 604, three died of CMV pneumonia on days 160, 268, and 280, one died with veno-occlusive disease of the liver on day 34, one died of complications of chronic GVHD on day 215, and one died on day 360 after relapse. The deaths in patients transplanted during AP were due to posttransplant relapse and occurred on days 642 and 847 after transplant. Figure 2 presents the Kaplan Meier statistics on survival for patients in this study characterized on the basis of the CSSBU being above or below the median. The difference between the two groups was not statistically significant (P = .33, power = 0.26 to detect a difference between 0.82 and 0.64 [Fig 2]). View larger version (14K): [in this window] [in a new window]   Fig 2. Kaplan Meier statistics on the survival of patients transplanted for CML in CP or AP categorized on the basis of BU steady state concentrations (CSSBU) greater than or less than the median (917 ng/mL) during conditioning. Patients were censored on the date of last contact. Tic marks denote survivors. The difference between the groups is not statistically significant (P = .33) In univariable Cox analysis, there was no statistically significant association of survival with any of the variables examined. Nonrelapse Mortality As described above, there were eight deaths in patients who had not relapsed. Four of the patients with CSSBU below the median died on days 34, 215, 280, and 604 of VOD, chronic GVHD, CMV pneumonia, and disseminated aspergillus infection, respectively. Two patients with CSSBU above the median died of disseminated aspergillus infection on days 114 and 211, and two died of CMV pneumonia on days 160 and 268. The cumulative incidence of death without relapse was 0.208 in patients with CSSBU below the median and 0.176 in patients with CSSBU above the median. These incidences were not significantly different. GVHD Acute GVHD. One patient (CSSBU 833 ng/mL) developed grade 4 acute GVHD and died of VOD on day 34. Grade 3 acute GVHD developed in two patients in the group with CSSBU below the median and five patients with levels above the median. The cumulative incidence of grade 2 or worse acute GVHD was 0.57 in patients in the group with levels above the median and 0.54 in the group with levels below the median (P = .94). Chronic GVHD. Of the 23 patients with CSSBU above the median, 17 (74%) developed clinically extensive chronic GVHD and three of these died (one of aspergillosis on day 211 and two of CMV pneumonia on days 160 and 268). Of the 22 patients with CSSBU below the median, 14 developed clinically extensive chronic GVHD, and three of these died (one each of aspergillosis on day 604, CMV pneumonia on day 280, and pneumonia of unknown etiology on day 215). Status of Survivors Thirty patients survive in continuing remission (19 from the group of 23 patients with CSSBU above the median value and 11 from the 22 patients with values below the median). There was no significant difference in the distribution of Karnofsky scores between the two groups, although two of the patients with the higher CSSBU and none of those with the lower levels had scores of less than 80. Table 3 presents the Karnofsky scores for these patients.   View this table: [in this window] [in a new window]   Table 3. Karnofsky Scores of Disease-Free Survivors     DISCUSSION Abstract Introduction Methods Results Discussion References This study demonstrates a significantly increased risk of recurrent disease in patients with CSSBU below the median level during conditioning with the BU + CY regimen used in this study. No relapses occurred among patients who achieved BU levels above the median. The increased rate of relapse was not mediated by graft rejection, and BU levels were not significantly associated with survival, RRT, speed of engraftment, the incidence of acute or chronic GVHD, or the Karnofsky scores of disease-free survivors. The lack of an association of CSSBU with graft rejection agrees with our previous report10 of a relationship between CSSBU and graft rejection in patients receiving grafts from HLA-identical siblings. In that study, rejection was observed only at CSSBU less than 200 ng/mL, ie, substantially lower than the lowest CSSBU observed in the present study (642 ng/mL). The absence of severe (grade 3 or 4) RRT at CSSBU higher than 900 ng/mL contrasts with the higher incidence previously reported.10 In the previous study, severe RRT was observed in four of 11 patients with CSSBU above 900 ng/mL, whereas, in the present study no severe RRT was observed in patients with CSSBU above the median (917 ng/mL). The previous report included patients with a variety of diagnoses. In that study, only one of the patients with severe RRT had CML, and the others had diagnoses of acute myelogenous leukemia, multiple myeloma, and myelodysplasia. The relationship between RRT and BU plasma concentration reported in our previous study was in general agreement with that reported by others.11 It is likely that the ability to tolerate higher CSSBU in BU + CY regimens is diagnosis-dependent and perhaps reflects a more intensive use of prior cytotoxic therapy in patients transplanted for conditions other than CML. We have reported elsewhere that adjustment of the oral BU dose based on first dose pharmacokinetics resulted in BU plasma levels within 10% of the target.12 Given the findings reported here, we have revised our current protocol for allogeneic marrow transplantation of patients with CML in CP by incorporating this dose-adjustment strategy to ensure that the CSSBU is at least 900 ng/mL. We are not adjusting BU doses downward because we have not observed an increased risk of severe RRT in CML patients treated with this regimen and achieving high CSSBU. Maintaining CSSBU above 900 ng/mL may result in a reduced relapse rate compared with the overall relapse rate seen in this study and previously6 in patients receiving BU + CY conditioning.     FOOTNOTES    Submitted August 27, 1996; accepted December 4, 1996.    Supported by Grants No. CA 15704, CA 18029, CA 18221, and CA 09515 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.    Address reprint requests to R.A. Clift, FIMLS, The Fred Hutchinson Cancer Research Center, 1124 Columbia St, Seattle, WA 98104-2092.    The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hearly marked ``advertisment'' in accordance with 18 U.S.C. section 1734 solely to indicate this fact.     REFERENCES Abstract Introduction Methods Results Discussion References 1. Clift RA, Buckner CD, Thomas ED, Doney K, Fefer A, Neiman PE, Singer J, Sanders J, Stewart P, Sullivan KM, Deeg J, Storb R: Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 2:621, 1982[Medline] [Order article via Infotrieve] 2. Goldman JM, Baughan ASJ, McCarthy DM, Worsley AM, Hows JM, Gordon-Smith EC, Catovsky D, Batchelor JR, Goolden AWG, Galton DAG: Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 2:623, 1982[Medline] [Order article via Infotrieve] 3. McGlave PB, Arthur DC, Kim TH, Ramsay NKC, Hurd DD, Kersey J: Successful allogeneic bone marrow transplantation for patients in the accelerated phase of chronic granulocytic leukaemia. Lancet 2:625, 1982[Medline] [Order article via Infotrieve] 4. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155, 1986 5. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AWG, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG: Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314:202, 1986[Abstract] 6. Clift RA, Appelbaum FR, Thomas ED: Treatment of chronic myeloid leukemia by marrow transplantation. Blood 82:1954, 1993 (review) 7. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, Masaoka T, McGlave PB, Messner H, O'Reilly RJ, Reiffers J, Rimm AA, Speck B, Veum-Stone JA, Wingard JR, Zwaan FE, Bortin MM: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235, 1993[Abstract/Free Full Text] 8. Buckner CD, Clift RA: Timing of allogeneic marrow transplants for patients with chronic myeloid leukemia. Bone Marrow Transplant 15:S203, 1995 9. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036, 1994[Abstract/Free Full Text] 10. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR, Hansen JA: Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16:31, 1995[Medline] [Order article via Infotrieve] 11. Vassal G: Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: Rationale and pitfalls. Anticancer Res 14:2363, 1994 (review) 12. Demirer T, Buckner CD, Appelbaum FR, Lambert K, Bensinger WI, Clift R, Storb R, Slattery JT: Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 17:341, 1996[Medline] [Order article via Infotrieve] 13. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986[Abstract] 14. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden R, Deeg HJ, Doney K, Martin PJ, Sullivan KM, Sanders J, Witherspoon RP: Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 80:1838, 1992[Abstract/Free Full Text] 15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED: Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825, 1995[Medline] [Order article via Infotrieve] 16. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney K, McDonald GB, Sanders JE, Sullivan KM, Storb R, Thomas ED, Witherspoon RP, Lomen P, Hannigan J, Hansen JA: A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 76:1464, 1990[Abstract/Free Full Text] 17. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, Storb R, Hansen JA: A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 77:1821, 1991[Abstract/Free Full Text] 18. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, Loughran TP, Hill R, Shields A, Yee G, Shulman H, Nims J, Strom S, Thomas ED: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 72:555, 1988[Abstract/Free Full Text] 19. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR, McGuffin R, McDonald GB, Meyers J, Schubert MM, Gauvreau J, Shulman HM, Sale GE, Anasetti C, Loughran TP, Strom S, Nims J, Thomas ED: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72:546, 1988[Abstract/Free Full Text] 20. Hansen JA, Mickelson EM, Choo SY, Petersdorf EW, Anasetti C, Martin PJ, Thomas ED: Clinical bone marrow transplantation: Donor selection and recipient monitoring, in Rose NR, De Macario EC, Fahey JL, Friedman H, Penn GM (eds): Manual of Clinical Laboratory Immunology. Washington, DC, American Society of Microbiology, 1992, p 850 21. Petersdorf EW, Smith AG, Mickelson EM, Martin PJ, Hansen JA: Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain. Immunogenetics 33:267, 1991[Medline] [Order article via Infotrieve] 22. Mickelson E, Smith A, McKinney S, Anderson G, Hansen JA: A comparative study of HLA-DRB1 typing by standard serology and hybridization of non-radioactive sequence-specific oligonucleotide probes to PCR-amplified DNA. Tissue Antigens 41:86, 1993[Medline] [Order article via Infotrieve] 23. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562, 1988[Abstract/Free Full Text] 24. Durnam DM, Anders KR, Fisher L, O'Quigley JO, Bryant EM, Thomas ED: Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood 74:2220, 1989[Abstract/Free Full Text] 25. Scharf SJ, Smith AG, Hansen JA, McFarland C, Erlich HA: Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 85:1954, 1995[Abstract/Free Full Text] 26. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598, 1995[Abstract/Free Full Text] 27. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173, 1993[Abstract/Free Full Text] 28. Goodrich JM, Boeckh M, Bowden R: Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 19:287, 1994[Medline] [Order article via Infotrieve] 29. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation A randomized double-blind study. Blood 88:4063, 1996[Abstract/Free Full Text] 30. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA: Efficacy and safety of fluconazole for fungal infections after marrow transplant A prospective, randomized, double-blind study. J Infect Dis 171:1545, 1995[Medline] [Order article via Infotrieve] 31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958 32. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966[Medline] [Order article via Infotrieve] 33. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R: Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: Motivation for and description of new methods. Br J Haematol 83:602, 1993[Medline] [Order article via Infotrieve] © 1997 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. Johnson, P. J. Orchard, K. S. Baker, R. Brundage, Q. Cao, X. Wang, E. Langer, S. F.-E. Maasah, J. A. Ross, R. Remmel, et al. Glutathione S-Transferase A1 Genetic Variants Reduce Busulfan Clearance in Children Undergoing Hematopoietic Cell Transplantation J. Clin. Pharmacol., September 1, 2008; 48(9): 1052 - 1062. [Abstract] [Full Text] [PDF] C. Chang, B. E. Storer, B. L. Scott, E. M. Bryant, H. M. Shulman, M. E. Flowers, B. M. Sandmaier, R. P. Witherspoon, R. A. Nash, J. E. Sanders, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders Blood, August 15, 2007; 110(4): 1379 - 1387. [Abstract] [Full Text] [PDF] V. G. Oehler, T. Gooley, D. S. Snyder, L. Johnston, A. Lin, C. C. Cummings, S. Chu, R. Bhatia, S. J. Forman, R. S. Negrin, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Blood, February 15, 2007; 109(4): 1782 - 1789. [Abstract] [Full Text] [PDF] B. P. Booth, A. Rahman, R. Dagher, D. Griebel, S. Lennon, D. Fuller, C. Sahajwalla, M. Mehta, and J. V. S. Gobburu Population Pharmacokinetic-Based Dosing of Intravenous Busulfan in Pediatric Patients J. Clin. Pharmacol., January 1, 2007; 47(1): 101 - 111. [Abstract] [Full Text] [PDF] M. J. Mauro and R. T. Maziarz Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used? Mayo Clin. Proc., March 1, 2006; 81(3): 404 - 416. [Abstract] [Full Text] [PDF] L. Giaccone, J. S. McCune, M. B. Maris, T. A. Gooley, B. M. Sandmaier, J. T. Slattery, S. Cole, R. A. Nash, R. F. Storb, and G. E. Georges Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation Blood, December 15, 2005; 106(13): 4381 - 4388. [Abstract] [Full Text] [PDF] Y. Takamatsu, K. Ogata, K. Yamauchi, S. Hara, T. Kamimura, S. Hayashi, J. Suzumiya, and K. Tamura An Evaluation of Busulfan Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation Jpn. J. Clin. Oncol., July 1, 2005; 35(7): 400 - 403. [Abstract] [Full Text] [PDF] K. Robien, C. M. Ulrich, J. Bigler, Y. Yasui, T. Gooley, B. Bruemmer, J. D. Potter, and J. P. Radich Methylenetetrahydrofolate Reductase Genotype Affects Risk of Relapse after Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia Clin. Cancer Res., November 15, 2004; 10(22): 7592 - 7598. [Abstract] [Full Text] [PDF] M. de Lima, A. Anagnostopoulos, M. Munsell, M. Shahjahan, N. Ueno, C. Ippoliti, B. S. Andersson, J. Gajewski, D. Couriel, J. Cortes, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood, August 1, 2004; 104(3): 865 - 872. [Abstract] [Full Text] [PDF] R. M. Stone Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach Oncologist, June 1, 2004; 9(3): 259 - 270. [Abstract] [Full Text] [PDF] H. J. Deeg, T. A. Gooley, M. E. D. Flowers, G. E. Sale, J. T. Slattery, C. Anasetti, T. R. Chauncey, K. Doney, G. E. Georges, H.-P. Kiem, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis Blood, December 1, 2003; 102(12): 3912 - 3918. [Abstract] [Full Text] [PDF] M. Bornhauser, B. Storer, J. T. Slattery, F. R. Appelbaum, H. J. Deeg, J. Hansen, P. J. Martin, G. B. McDonald, W. G. Nichols, J. Radich, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells Blood, August 1, 2003; 102(3): 820 - 826. [Abstract] [Full Text] [PDF] J. P. Radich, T. Gooley, W. Bensinger, T. Chauncey, R. Clift, M. Flowers, P. Martin, J. Slattery, D. Sultan, and F. R. Appelbaum HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen Blood, July 1, 2003; 102(1): 31 - 35. [Abstract] [Full Text] [PDF] G. B. McDonald, J. T. Slattery, M. E. Bouvier, S. Ren, A. L. Batchelder, T. F. Kalhorn, H. G. Schoch, C. Anasetti, and T. Gooley Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation Blood, March 1, 2003; 101(5): 2043 - 2048. [Abstract] [Full Text] [PDF] H. J. Deeg, B. Storer, J. T. Slattery, C. Anasetti, K. C. Doney, J. A. Hansen, H.-P. Kiem, P. J. Martin, E. Petersdorf, J. P. Radich, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome Blood, July 30, 2002; 100(4): 1201 - 1207. [Abstract] [Full Text] [PDF] W. P. Petros, G. Broadwater, D. Berry, R. B. Jones, J. J. Vredenburgh, C. J. Gilbert, J. P. Gibbs, O. M. Colvin, and W. P. Peters Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 698 - 705. [Abstract] [Full Text] [PDF] B. J. Druker, S. G. O'Brien, J. Cortes, and J. Radich Chronic Myelogenous Leukemia Hematology, January 1, 2002; 2002(1): 111 - 135. [Abstract] [Full Text] G. Socie, R. A. Clift, D. Blaise, A. Devergie, O. Ringden, P. J. Martin, M. Remberger, H. J. Deeg, T. Ruutu, M. Michallet, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies Blood, December 15, 2001; 98(13): 3569 - 3574. [Abstract] [Full Text] [PDF] R. P. Witherspoon, H. J. Deeg, B. Storer, C. Anasetti, R. Storb, and F. R. Appelbaum Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia J. Clin. Oncol., April 15, 2001; 19(8): 2134 - 2141. [Abstract] [Full Text] [PDF] G. R. Westerhof, R. E. Ploemacher, A. Boudewijn, I. Blokland, J. H. Dillingh, A. T. McGown, J. A. Hadfield, M. J. Dawson, and J. D. Down Comparison of Different Busulfan Analogues for Depletion of Hematopoietic Stem Cells and Promotion of Donor-Type Chimerism in Murine Bone Marrow Transplant Recipients Cancer Res., October 1, 2000; 60(19): 5470 - 5478. [Abstract] [Full Text] H. J. Deeg, H. M. Shulman, J. E. Anderson, E. M. Bryant, T. A. Gooley, J. T. Slattery, C. Anasetti, A. Fefer, R. Storb, and F. R. Appelbaum Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age Blood, February 15, 2000; 95(4): 1188 - 1194. [Abstract] [Full Text] [PDF] J. P. Gibbs, T. Gooley, B. Corneau, G. Murray, P. Stewart, F. R. Appelbaum, and J. T. Slattery The Impact of Obesity and Disease on Busulfan Oral Clearance in Adults Blood, June 15, 1999; 93(12): 4436 - 4440. [Abstract] [Full Text] [PDF] W. P. Petros and O. M. Colvin Metabolic Jeopardy with High-Dose Cyclophosphamide?--Not So Fast Clin. Cancer Res., April 1, 1999; 5(4): 723 - 724. [Full Text] [PDF] A. E. Woolfrey, T. A. Gooley, E. L. Sievers, L. A. Milner, R. G. Andrews, M. Walters, P. Hoffmeister, J. A. Hansen, C. Anasetti, E. Bryant, et al. Bone Marrow Transplantation for Children Less Than 2 Years of Age With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Blood, November 15, 1998; 92(10): 3546 - 3556. [Abstract] [Full Text] [PDF] J. P. Gibbs, J.-S. Yang, and J. T. Slattery Comparison of Human Liver and Small Intestinal Glutathione S-Transferase-Catalyzed Busulfan Conjugation in Vitro Drug Metab. Dispos., January 1, 1998; 26(1): 52 - 55. [Abstract] [Full Text] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Slattery, J.T. Articles by Appelbaum, F.R. Search for Related Content PubMed PubMed Citation Articles by Slattery, J.T. Articles by Appelbaum, F.R. Related Collections Transplantation Social Bookmarking                   What's this?

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020